We are thrilled to announce a strategic partnership between SyVento BioTech and Kymos Group, aimed at unlocking the full potential of the CDMO and CRO services offered by both companies.
By combining SyVento’s expertise in preclinical/clinical drug development, liposomal/LNP technologies and GMP manufacturing of clinical/ commercial batches with Kymos’ excellence in advanced bioanalytical and CMC services under GCP, GLP, GxP, and GMP standards for mRNA, oligonucleotides, lipids, and LNPs, this collaboration will deliver comprehensive solutions for RNA-based therapeutics. Together, we are opening new doors to breakthroughs in the biotech and pharmaceutical space.
We look forward to this journey of discovery, innovation, and shared success.
